Arrowhead Pharmaceuticals Inc. (ARWR) Financial Statements (2026 and earlier)

Company Profile

Business Address 177 E COLORADO BLVD
PASADENA, CA 91105
State of Incorp. DE
Fiscal Year End September 30
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
MRQ
9/30/2025
9/30/2024
9/30/2023
9/30/2022
9/30/2021
9/30/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments692,818578,276292,735268,391367,789315,492
Cash and cash equivalent     184,434143,583
Short-term investments692,818578,276292,735268,391183,355171,909
Restricted cash and investments1,9003,5007,9007,300  
Receivables6,824  1,41010,255846
Prepaid expense10,9339,5378,8137,2894,3624,251
Contract with customer, asset, after allowance for credit loss      
Other current assets13,5164,9737,08220,2042,1911,782
Other undisclosed current assets224,64899,185102,991100,705  
Total current assets:950,639695,471419,521405,299384,597322,370
Noncurrent Assets
Operating lease, right-of-use asset43,89145,25545,29758,29117,34616,137
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization382,515386,032290,262110,29748,67530,881
Long-term investments and receivables    105,872245,595137,487
Long-term investments    105,872245,595137,487
Intangible asset, including goodwill, after accumulated amortization6,8618,56210,26211,96213,66315,363
Intangible asset, excluding goodwill, after accumulated amortization6,8618,56210,26211,96213,66315,363
Other noncurrent assets1,3894,482210218272265
Total noncurrent assets:434,656444,331346,031286,640325,551200,133
TOTAL ASSETS:1,385,2951,139,802765,552691,939710,148522,504
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities108,09374,40575,62961,97533,23120,278
Employee-related liabilities12,2519,7738,061
Accounts payable17,67411,38835,8662,8689,4576,829
Accrued liabilities90,41963,01739,76346,85614,0015,389
Deferred revenue2,399 86674,099111,05519,291
Debt40,000     
Other liabilities10,811432435  17
Other undisclosed current liabilities34,18428,33128,5262,7762,2501,095
Total current liabilities:195,487103,168105,456138,850146,53640,681
Noncurrent Liabilities
Long-term debt and lease obligation214,883393,183 78,80023,29520,043
Long-term debt, excluding current maturities214,883393,183    
Liabilities, other than long-term debt104,112111,027104,60855,950131,495 
Deferred revenue   55,950131,495 
Operating lease, liability104,112111,027104,60878,80023,29520,043
Other undisclosed noncurrent liabilities367,397341,361268,326  (20,043)
Total noncurrent liabilities:686,392845,571372,934134,750154,79020,043
Total liabilities:881,879948,739478,390273,600301,32660,725
Equity
Equity, attributable to parent466,052185,444271,343398,520408,822461,779
Common stock231217200198197195
Treasury stock, value(53,193)     
Additional paid in capital2,139,7251,806,0001,300,3951,219,2131,053,386965,410
Accumulated other comprehensive income (loss)6,4434,750(3,222)(136)(69)18
Accumulated deficit(1,627,154)(1,625,523)(1,026,030)(820,755)(644,692)(503,844)
Equity, attributable to noncontrolling interest37,3645,61915,81919,819  
Total equity:503,416191,063287,162418,339408,822461,779
TOTAL LIABILITIES AND EQUITY:1,385,2951,139,802765,552691,939710,148522,504

Income Statement (P&L) ($ in thousands)

12/31/2025
TTM
9/30/2025
9/30/2024
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Revenues829,4483,551240,735243,231138,28787,992
Gross profit:829,4483,551240,735243,231138,28787,992
Operating expenses(731,102)(604,631)(445,737)(421,738)(287,323)(181,151)
Operating income (loss):98,346(601,080)(205,002)(178,507)(149,036)(93,159)
Nonoperating income (expense)(46,813)(11,380)(1,489)5,7988,1908,608
Investment income, nonoperating37,28922,72015,299   
Other nonoperating income (expense)5,259(1,748)1,5387652,070(583)
Interest and debt expense(89,361)(32,352)(18,326)   
Income (loss) from continuing operations before equity method investments, income taxes:(37,828)(644,812)(224,817)(172,709)(140,846)(84,551)
Other undisclosed income from continuing operations before income taxes89,36132,35218,326   
Income (loss) from continuing operations before income taxes:51,533(612,460)(206,491)(172,709)(140,846)(84,551)
Income tax expense (benefit)(21,419)2,767(2,784)(3,785)(2)(2)
Income (loss) from continuing operations:30,114(609,693)(209,275)(176,494)(140,848)(84,553)
Loss before gain (loss) on sale of properties:(176,494)(140,848)(84,553)
Net income (loss):30,114(609,693)(209,275)(176,494)(140,848)(84,553)
Net income (loss) attributable to noncontrolling interest(31,745)10,2004,000431  
Net income (loss) available to common stockholders, diluted:(1,631)(599,493)(205,275)(176,063)(140,848)(84,553)

Comprehensive Income ($ in thousands)

12/31/2025
TTM
9/30/2025
9/30/2024
9/30/2023
9/30/2022
9/30/2021
9/30/2020
Net income (loss):30,114(609,693)(209,275)(176,494)(140,848)(84,553)
Other undisclosed comprehensive income (loss)1,6937,972(3,086)(67)  
Comprehensive income (loss):31,807(601,721)(212,361)(176,561)(140,848)(84,553)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(31,745)10,2004,000431  
Other undisclosed comprehensive income (loss), net of tax, attributable to parent     (87)410
Comprehensive income (loss), net of tax, attributable to parent:62(591,521)(208,361)(176,130)(140,935)(84,143)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: